Global WuXi Webinar: Pioneering Approaches to Dismantling Cancer

Significant advances have been made to unravel cancer’s mysteries and complexities at the genetic, molecular, and pathway levels. These advances not only reveal new scientific insights into the biology of the...

WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for...

We are pleased to announce that we have formed a strategic alliance with MedImmune, the global biologics research and development arm of AstraZeneca to bring cutting-edge research and technical capability for...

WuXi and Lilly Collaborate to Develop Novel Therapeutics in China

We are pleased to share with you that we have entered into a strategic collaboration with Eli Lilly and Company to develop, manufacture and commercialize a novel small molecule in China...

Gilead Sciences and WuXi Partner for a Dedicated Analytical and Stability Testing Facility

We are pleased to announce that we have entered into a strategic partnership with Gilead Sciences to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major...